CEO Update: December 2021

CEO Update: December 2021

InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in process development work, published and presented INSB200™ data, and closed an additional institutional funding round. For additional...
CEO Update: August 2021

CEO Update: August 2021

InSitu Biologics has had a very productive summer. We received positive pre-clinical animal study results on our lead product, had positive regulatory interactions with the FDA, further developed our manufacturing capabilities, and made progress towards future funding...